Carmel Pharma
Manufacture and distribution of products that improve the quality of life of people who prepare,.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (6 %) | 17 % | 12 % | - | 21 % | 5 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 81 % | 77 % | 103 % | 103 % | 100 % | 115 % | 125 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Carmel Pharma, a Swedish company founded in 1994, developed the PhaSeal® System, a closed-system drug transfer device (CSTD) designed to ensure the safe handling of hazardous drugs. The company's core business revolves around enhancing healthcare worker safety by preventing exposure to toxic substances, such as chemotherapy drugs, during preparation and administration. Its primary clients include hospital pharmacies, oncology nurses, pharmacy technicians, and oncologists in both inpatient and outpatient settings.
The company's key product, the PhaSeal system, is a mechanically and microbiologically closed device that prevents the escape of drug vapors and leaks. This is achieved through a unique membrane-to-membrane technology that creates an airtight, leak-proof connection during the transfer of drugs from vials to syringes and then to IV bags. Key components include the Protector, which attaches to the drug vial to equalize pressure; the Injector, for transferring the drug; and various connectors for IV lines. This system not only protects healthcare professionals but also maintains the sterility of the medication.
Carmel Pharma established a U.S. presence in 1999 with an office and distribution facility in Columbus, Ohio. By 2011, the PhaSeal System was being used in over 1,000 facilities across more than 30 countries. In August 2011, recognizing the growth potential in the healthcare worker safety market, the global medical technology company Becton, Dickinson and Company (BD) acquired Carmel Pharma. The acquisition integrated the PhaSeal platform into BD's broader suite of safety products, leveraging BD's extensive market reach to accelerate adoption.
Keywords: closed-system drug transfer device, CSTD, hazardous drug handling, healthcare worker safety, oncology pharmacy, chemotherapy safety, parenteral medication, drug preparation, medication administration, vial transfer system, Becton Dickinson, BD PhaSeal, drug exposure prevention, aseptic technique, medical device, pharmaceutical safety, hospital pharmacy solutions, cytotoxic protection, leak-proof drug transfer, IV drug delivery